<DOC>
	<DOCNO>NCT02985632</DOCNO>
	<brief_summary>An oral dose BMS-986141 administer Hepatic Impairment Healthy Participants evaluate pharmacokinetics patient population .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetics BMS-986141 Participants With Hepatic Impairment Compared Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Women childbearing potential ( WNOCBP ) , male , age 18 70 year , inclusive . BMI 20.0 38.0 kg/m2 inclusive Participants history normal renal function Subjects hepatic impairment must stable dose medication and/or treatment regimen Healthy subject extent possible match four subject hepatic impairment regard body weight , age gender , determine clinically significant deviation normal medical history , physical examination , ECGs , clinical laboratory determination Any nonhepatic significant acute chronic medical illness could affect participant safety data interpretation determine investigator . History recurrent dizziness fall risk within 4 week study drug administration History primarily cholestatic liver disease , autoimmune liver disease , metastatic liver disease active alcoholic hepatitis History know bleed diathesis coagulation disorder ( eg , thrombotic thrombocytopenic purpura ) Other protocol define exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>